User profiles for Lorenzo Salvati
 | Lorenzo SalvatiDepartment of Experimental and Clinical Medicine, University of Florence, Firenze, ITALY Verified email at unifi.it Cited by 1565 |
[HTML][HTML] Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
BACKGROUND Coronavirus disease 19 (COVID-19) is an emerging infectious disease
caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; …
caused by SARS-CoV-2. Antiviral immune response is crucial to achieve pathogen clearance; …
[HTML][HTML] First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19
The characterization of the adaptive immune response to COVID-19 vaccination in individuals
who recovered from SARS-CoV-2 infection may define current and future clinical practice. …
who recovered from SARS-CoV-2 infection may define current and future clinical practice. …
[HTML][HTML] Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab
The current pandemic emergence of novel coronavirus disease (COVID-19) poses a relevant
threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical …
threat to global health. SARS-CoV-2 infection is characterized by a wide range of clinical …
Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients
…, M Capone, M Spinicci, L Salvati… - European Journal of …, 2020 - Wiley Online Library
The characterization of cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2
is fundamental to understand COVID‐19 progression and the development of …
is fundamental to understand COVID‐19 progression and the development of …
[HTML][HTML] SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies
…, M Capone, N Di Lauria, L Salvati… - The Journal of …, 2022 - Am Soc Clin Investig
BACKGROUND Immunization against SARS-CoV-2, the causative agent of COVID-19, occurs
via natural infection or vaccination. However, it is currently unknown how long infection- or …
via natural infection or vaccination. However, it is currently unknown how long infection- or …
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
One and half year following the occurrence of COVID-19 pandemic, significant efforts from
laboratories all over the world generated a huge amount of data describing the prototypical …
laboratories all over the world generated a huge amount of data describing the prototypical …
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS‐CoV‐2 infection
SARS‐CoV‐2 is responsible for a new infectious disease (COVID‐19) in which individuals
can either remain asymptomatic or progress from mild to severe clinical conditions including …
can either remain asymptomatic or progress from mild to severe clinical conditions including …
Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study
Background The early identification of patients at risk of clinical deterioration is of interest
considering the timeline of COVID-19 after the onset of symptoms. Objective The aim of our …
considering the timeline of COVID-19 after the onset of symptoms. Objective The aim of our …
[HTML][HTML] SARS-CoV-2 spike-specific CD4+ T cell response is conserved against variants of concern, including omicron
…, M Capone, G Lamacchia, L Salvati… - Frontiers in …, 2022 - frontiersin.org
Although accumulating data have investigated the effect of SARS-CoV-2 mutations on antibody
neutralizing activity, less is known about T cell immunity. In this work, we found that the …
neutralizing activity, less is known about T cell immunity. In this work, we found that the …
The impact of targeted therapies and immunotherapy in melanoma brain metastases: a systematic review and meta‐analysis
Background Targeted therapies (TT), combination immunotherapy (CMI), and monoimmunotherapy
(MI) in combination with radiotherapy (CRI) or not are commonly used in patients …
(MI) in combination with radiotherapy (CRI) or not are commonly used in patients …
